Condition Directory

Type 2 Diabetes clinical trials

Directory of U.S. ClinicalTrials.gov public records for Type 2 Diabetes. Browse Type 2 Diabetes recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced September 7, 2026 Report an issue

ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

589

Shown on this page

Current sort

How Type 2 Diabetes studies are organized in the registry

Type 2 diabetes records also appear under generic “diabetes” and the abbreviation T2DM, so checking both phrasings gives fuller coverage. The portfolio spans drug trials, lifestyle programs, and large cardiovascular-outcome studies; the study-type filter separates the observational cohorts from interventional trials.

Terms that often appear in related listings

T2DM metformin cardiovascular outcomes lifestyle intervention

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 589 matching trials for Type 2 Diabetes.

Live ClinicalTrials.gov results.

Active filters: "T2DM" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: Maridebart Cafraglutide, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 27
States / cities: Gilbert, Arizona • Canoga Park, California • Cerritos, California + 22 more

Conditions: Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
Interventions: Elecoglipron, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 33
States / cities: Sun City, Arizona • Surprise, Arizona • Concord, California + 29 more

Conditions: Diabetes Mellitus, Type 2
Interventions: MTM, Food Subsidy; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
Interventions: aleniglipron, Placebo; Drug
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 74
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 68 more

Conditions: Diabetes Mellitus, Type 2, HIV Infections, PreDiabetes
Interventions: MTM + ILI, Standard MTM; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Type 2 Diabetes Mellitus
Interventions: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 27
States / cities: Birmingham, Alabama • Daphne, Alabama • Lomita, California + 24 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Huntsville, Alabama • Mobile, Alabama • Sheffield, Alabama + 36 more

Conditions: Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults
Interventions: Calcium-HMB Plus Vitamin D3, Matching placebo; Dietary Supplement · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 65 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Type 2 Diabetes
Interventions: Procedure: assessment; Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Peoria, Arizona • Little Rock, Arkansas • Lincoln, California + 11 more

Conditions: Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Digestive System Diseases, Type 2 Diabetes Mellitus (T2DM)
Interventions: HTD1801, Placebo; Drug
Lead sponsor: HighTide Therapeutics (Hong Kong) Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 17
States / cities: Chandler, Arizona • Tucson, Arizona • Panorama City, California + 12 more

Conditions: Type 2 Diabetes Mellitus, Binge-Eating Disorder, Binge Eating, Obesity
Interventions: Appetite Awareness Training (AAT), Diabetes Prevention Program (DPP); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 25 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetes Mellitus, Type 2, Diet, Healthy
Interventions: Healthy Food Delivery Intervention, CDCES Consultation Only; Behavioral
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 13
States / cities: Batesville, Arkansas • Corning, Arkansas • Eureka Springs, Arkansas + 9 more

About this Type 2 Diabetes clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Type 2 Diabetes as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Type 2 Diabetes.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Type 2 Diabetes clinical trials

How Type 2 Diabetes studies are organized in the registry

Filter and sort this condition

Live official records

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Food As MedicinE for Diabetes

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Food as Medicine for HIV and Diabetes

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Preventing Type 2 Diabetes in Black Emergent Adult

Home Food Delivery for Diabetes Management in Patients of Rural Clinics

About this Type 2 Diabetes clinical trials directory page